Journal of Experimental Medicine Cover Letter

This page was checked against JEM's live Rockefeller University Press submission guidelines and transfer instructions on July 15, 2026. Those official pages establish the cover-letter inputs, format-neutral first-submission route, Article and Brief Definitive Report types, title and abstract limits, data-access option, reviewer-exclusion limit, and transfer packet. The interpretation layer comes from Manusights pre-submission review work: it tests whether the title, abstract, summary, evidence figures, Source Data, methods, and letter make the same mechanism-to-disease argument. That distinction matters because JEM does not publish a private checklist for editorial decisions.

JEM's current Editors & Staff page lists Executive Editor: Natalie Cain. Address the letter to “Journal of Experimental Medicine Editors” unless an editor has invited or explicitly requested the submission; a name alone is not a reason to direct a routine manuscript to one person.

Publication-cost choices belong outside the letter, but authors should confirm them before submitting: JEM's current official fees page lists a $2,500 green-access page charge and a $6,000 Gold Open Access APC. Do not use the cover letter to argue ability to pay; it does not change editorial fit.

Weak: We report a novel immune pathway that may have implications for disease.

Stronger: We show that macrophage-specific loss of pathway X sustains fibrotic lung injury by preventing resolution of the epithelial repair program; perturbation, patient tissue, lineage tracing, and rescue experiments establish the causal mechanism and disease consequence.

The stronger opener identifies the mechanism, disease context, causal evidence, and experimental-medicine implication. It does not make the editor infer why a compelling phenotype belongs in JEM.

Across JEM-targeted immunology, infection, cancer, inflammation, vascular biology, and disease-model manuscripts, the recurring problem is an uneven bridge. A disease phenotype can be striking while the causal chain remains thin. Or an elegant mechanism can be real while the disease consequence appears only in the introduction. These are author-side checks, not private JEM criteria; they help make the public conceptual-advance requirement inspectable across the title, abstract, summary, figures, methods, Source Data, and cover letter.

Disease phenotype without a causal mechanism

For Journal of Experimental Medicine, if the letter relies on a disease association, pathology image, patient correlation, or treatment response, identify the experiment that establishes causation: perturbation, rescue, lineage restriction, orthogonal model, temporal test, or human validation. If the work cannot support a mechanistic claim, frame it honestly and consider whether a clinical or disease-specialty journal is the better route.

Mechanism with decorative disease relevance

Strong cell biology or immunology can still be poorly routed to Journal of Experimental Medicine when disease context is appended late. A credible JEM letter explains how the mechanism changes disease biology, not merely why disease is an interesting possible application. Point to the model, patient material, intervention, or translational consequence that carries this bridge.

Related work and transfer history are concealed

The official guidance explicitly requests related or competing papers, and JEM's transfer guidance welcomes another journal's reviewer comments. A cover letter should make the overlap boundary easier to evaluate. For a transfer, name the previous journal, request transfer consideration, and state which decision letters and responses are supplied. Do not present a transferred manuscript as if the prior review did not occur.

Data accessibility is claimed without an audit path

JEM lets authors tell editors when original data are archived and accessible for review. Name the actual repository, accession, controlled-access mechanism, or reason access must be limited. Avoid saying “data are available” when raw images, source data, code, clinical materials, or animal-study records cannot be produced through the stated route.

Phenotype-first route mismatch. The letter emphasizes severity, a biomarker, or a therapeutic response but does not name the causal mechanism.

Check the JEM mechanism-disease bridge.

Transfer-context gap. A manuscript has been reviewed elsewhere, but the letter omits the previous journal, comments, and response that JEM says it can consider.

Data-access overclaim. The letter says original data are available without identifying an archive or controlled access path.

Reviewer-field misuse. Suggested reviewers are not aligned to the mechanism and disease expertise, or exclusions exceed three or lack a real conflict basis.

• The letter names the conceptual advance in the first paragraph.
• The mechanism-disease bridge is explicit and supported by named evidence.
• Related and competing work, conflicts, inquiry, preprint, and transfer context are disclosed where relevant.
• Data access is real and matches the manuscript and Source Data package.
• Editor request, reviewers, and up to three exclusions follow the current JEM route.
• Articles and Brief Definitive Reports are not confused with Reviews or Perspectives requiring prior contact.

• Journal of Experimental Medicine submission guide